The study highlights the benefits of insulin pen therapy for type 2 diabetes

A new study provides clinical evidence for insulin therapy in type 2 diabetes patients with insulin pens.
The largest randomized controlled trial in the United States compared the efficacy and safety of multiple daily insulin pen injections in patients with poorly controlled type 2 diabetes mellitus.
331 patients were recruited from the age of 30 to 75 years old. Following is the time to establish dosage optimization for a month or two. Patients are randomly assigned to insulin pen therapy for six months, which is called the randomization stage.
Over the next six months, the researchers analyzed changes in average glycosylated hemoglobin between assessment groups starting at the end of the year.
Six months later, patients treated with insulin pen had better glycemic control. One year later, patients switching to insulin pen therapy achieved a further reduction in glycosylated hemoglobin and required less insulin. Both groups were treated with 13 millimoles/moles (1.2%) and their HbA1c levels were reduced compared with the 12-month marker baseline.